Respiratory System
Respiratory
High-yield pulmonary for USMLE Step 2/3 — built on a 13-episode pathophysiology backbone covering surfactant, lung volumes, pressures, VQ physiology, and gas exchange, with dedicated episodes on PE, pulmonary HTN, pleural disease, lung cancer, COPD, sarcoidosis, OSA, and ventilator management.
Pulmonary Physiology Foundations
The 13-episode Pulmonary Pathophysiology series is the spine of this guide — working from surfactant and the Law of Laplace through lung volumes, alveolar and pleural pressures, gas delivery equations, A-a gradients, shunts, VQ mismatch, and the obstructive/restrictive distinction. Understanding these mechanisms cold means you can derive the answer to almost any pulmonary question rather than memorizing it.
EP392
Pulmonary Pathophysiology Series 1 — Surfactant, Law of Laplace, Alpha-1-AT
- Law of Laplace: Pressure to keep alveolus open = 2T/r. Small alveoli require MORE pressure — but have HIGHER surfactant concentration (same amount in smaller area), so surface tension is lower. This is the counter-balancing mechanism.
- Surfactant concentration, not amount: As alveoli shrink on exhalation, surfactant molecules crowd together → higher concentration → more surface tension reduction. Prevents atelectasis at low volumes.
- NRDS (neonatal RDS): Surfactant deficiency → alveolar collapse on exhalation → increased work of breathing → hypoxia. Born <34 wks → give maternal betamethasone (2 doses) to promote lung maturity. Also occurs in infants of diabetic mothers (hyperinsulinemia inhibits surfactant synthesis, even at term).
- PEEP mechanism: Positive end-expiratory pressure keeps alveoli partially distended between breaths → reduces work of breathing and prevents atelectasis. Used in ARDS management.
- Alpha-1-antitrypsin deficiency: Autosomal codominant. Defective/misfolded AAT accumulates in liver (↑LFTs, eventual liver damage) and fails to reach lungs → uncheck protease activity from macrophages → destroys lung parenchyma → decreased surface area for diffusion → hypoxia. Smoking dramatically accelerates disease.
- Aspiration pneumonia: Right lower lobe — right mainstem bronchus is wider and more vertical. Foreign body aspiration in children also → right lower lobe. Obstructing cancer → recurrent pneumonia same lobe.
Law of Laplace — The Core Framework
P = 2T/r — pressure needed to keep alveolus open is directly proportional to surface tension (T) and inversely proportional to radius (r).
| Scenario | Radius | Surface Tension | Net Effect |
|---|---|---|---|
| Small alveolus (exhalation) | Small → demands high P | ↑ Surfactant concentration → ↓ T | Offsets — alveolus stays open |
| Large alveolus | Large → lower P needed | Lower surfactant concentration | Stable at high volume |
| NRDS (no surfactant) | Collapses on exhale | High (no reduction) | Atelectasis, ↑ work, hypoxia |
| PEEP applied | Keeps radius larger | Less surface tension problem | Recruits alveoli, improves oxygenation |
Concentration Effect — Key Insight
It is the concentration of surfactant per unit area that matters, not the total amount. Smaller alveoli with the same absolute quantity of surfactant have a higher concentration → lower surface tension → resists collapse more effectively. This is why premature infants struggle — they don't produce enough to achieve adequate concentration.
Alpha-1-Antitrypsin Deficiency — Mechanism Chain
- Defective AAT (misfolded) accumulates in hepatocytes → liver disease (elevated LFTs, cirrhosis)
- Insufficient AAT reaches lungs → unprotected against macrophage-derived proteases (elastase)
- Proteases destroy alveolar parenchyma → ↓ surface area → ↓ diffusion capacity → hypoxia
- Smoking up-regulates macrophage protease activity → accelerates destruction dramatically
- Key NBME pearl: "Which intervention most reduces mortality?" → Stop smoking
NRDS and Diabetic Mother
- Infant of diabetic mother → fetal hyperglycemia → fetal hyperinsulinemia (beta-cell hyperplasia)
- Insulin interferes with surfactant synthesis → NRDS even at term gestation
- Postnatal: hyperinsulinemia persists → hypoglycemia, hypocalcemia → seizures
- Treatment: glucose therapy (for hypoglycemic seizures)
Aspiration Rules
Right mainstem bronchus: wider + more vertical = straight shot for aspirated material. Right lower lobe = most common site for aspiration pneumonia and foreign body. Obstruction from tumor → recurrent pneumonia always same lobe = consider lung cancer as underlying cause.
EP393
Pulmonary Pathophysiology Series 2 — Pulsus Paradoxus, Diaphragm, Asthma Overview
- Pulsus paradoxus mechanism: During inspiration, intrathoracic pressure ↓ → RV engulges with blood → RV expands into interventricular septum → LV cavity compressed → ↓ LV filling → ↓ stroke volume → ↓ SBP. Normal: SBP drops <10 mmHg. Paradoxus: >10 mmHg drop.
- What limits RV expansion: Normally RV bulges into pericardial space and thorax. In cardiac tamponade, COPD/hyperinflation, tension pneumothorax, or severe asthma — RV cannot expand outward → bulges MORE into LV septum → exaggerated SBP drop.
- Second mechanism — pulmonary artery compression: Hyperinflated lungs compress pulmonary arteries → ↓ blood reaching left heart → ↓ LV preload → ↓ CO → ↓ SBP.
- Diaphragm: Innervated by phrenic nerve (C3, C4, C5 — "C345 keeps the diaphragm alive"). During inspiration: descends → thoracic volume ↑ → intrathoracic pressure ↓ → venous return ↑. On imaging: one elevated hemidiaphragm = diaphragmatic paralysis (lung cancer invading phrenic nerve, GBS).
- Asthma definition: Episodic, reversible bronchoconstriction. IgE-mediated (Type I hypersensitivity). Key: FEV1/FVC ratio may be NORMAL between attacks (episodic nature). Methacholine challenge: muscarinic agonist causing bronchoconstriction at low doses only in hyperreactive airways.
- Asthma pathogenesis: Allergen → IgE on mast cell Fc-epsilon receptors → cross-linking → degranulation → histamine, leukotrienes, prostaglandins, eosinophil chemotactic factor. Late phase (hours later): eosinophil recruitment → more inflammation. Charcot-Leyden crystals = dead eosinophils on histology.
Pulsus Paradoxus — Conditions and Shared Mechanism
| Condition | Why RV Can't Bulge Out | Result |
|---|---|---|
| Cardiac tamponade | Pericardial fluid compresses RV | RV invades IVS → ↓ LV volume |
| COPD (hyperinflation) | Hyperinflated lungs occupy thoracic space | RV invades IVS + pulmonary artery compression |
| Severe asthma exacerbation | Air-trapped, hyperinflated lungs | Same as COPD mechanism |
| Tension pneumothorax | Air in thorax squishes RV | RV invades IVS |
Asthma Early vs Late Phase
Early phase (minutes): Allergen → mast cell degranulation → histamine, leukotrienes (LTC4, LTD4, LTE4), bradykinin → bronchoconstriction, airway edema, mucus.
Late phase (4–8 hrs): Eosinophil chemotactic factor recruits eosinophils → Charcot-Leyden crystals, Curschmann spirals (mucus casts). This late phase can be MORE severe than early — reason IV steroids are given in acute exacerbations (not just bronchodilators).
EP406
Pulmonary Pathophysiology Series 5 — Lung Volumes, Capacities & Dead Space
- Volumes (cannot be measured by spirometry alone): Tidal volume (TV) = quiet breath in/out. Inspiratory reserve volume (IRV) = extra you can breathe in above TV. Expiratory reserve volume (ERV) = extra you can exhale after TV. Residual volume (RV) = air remaining after maximal exhalation — cannot be measured by spirometry.
- Capacities = sum of ≥2 volumes: Total lung capacity (TLC) = all volumes added. Vital capacity (VC) = TLC − RV. Functional residual capacity (FRC) = RV + ERV = volume at rest (inward lung pull = outward chest wall recoil). Inspiratory capacity = TV + IRV.
- FRC = resting equilibrium: Lungs want to collapse inward; chest wall wants to spring outward. These forces balance at FRC → alveolar pressure = 0 (atmospheric). This is the lowest pulmonary vascular resistance state.
- Compliance = ΔV/ΔP: Compliant lung = large volume change per small pressure change (emphysema — parenchyma destroyed, too floppy). Non-compliant lung = small volume change per large pressure change (fibrosis, pulmonary edema — alveolar wall thickened). Lungs LESS compliant at high volumes (COPD patients have hyperinflated lungs = stiff at those volumes).
- Dead space: ~30% of inspired air does not participate in gas exchange. Anatomic dead space = conducting zone (nose to terminal bronchioles) — always present. Functional dead space = lung apices — can be recruited with exercise. Physiologic dead space = anatomic + functional (~150 mL). Ventilator → ↑ alveolar pressure → squishes apical capillaries → ↑ zone 1 lung = ↑ dead space.
- Minute ventilation: = TV × respiratory rate. Not all counts — dead space wasted.
Lung Volumes and Capacities Quick Reference
| Term | Definition | Normal | In Obstructive | In Restrictive |
|---|---|---|---|---|
| TV | Quiet breath | ~500 mL | Normal/↑ | ↓ |
| IRV | Extra above TV | ~3,000 mL | ↓ | ↓ |
| ERV | Extra below TV | ~1,200 mL | ↓ (air trapping) | ↓ |
| RV | After max exhale | ~1,200 mL | ↑↑ (air trapping) | ↓ |
| FRC | RV + ERV | ~2,400 mL | ↑ | ↓ |
| TLC | All volumes | ~6,000 mL | ↑ | ↓ |
| VC | TLC − RV | ~4,800 mL | ↓ | ↓ |
FRC — Why It Is the "Rest State"
At FRC, intra-alveolar pressure = zero (atmospheric). The natural inward recoil of the lung (surface tension from air molecules) is perfectly offset by the outward spring of the chest wall. This is exactly the condition where pulmonary vascular resistance is at its minimum — because alveolar vessels and extra-alveolar vessels are both at their happiest volume point.
Compliance — What Increases/Decreases It
- ↑ Compliance (too floppy): Emphysema — proteases destroy alveolar walls → less structural tissue → easier to inflate but collapses on exhale. Aging also increases compliance.
- ↓ Compliance (too stiff): Pulmonary fibrosis/ILD — thickened walls. Pulmonary edema — fluid-filled alveoli. NRDS — surface tension unopposed. Operating at HIGH lung volumes (COPD hyperinflation) — balloon analogy: fully inflated balloon needs huge force for tiny extra volume.
EP407
Pulmonary Pathophysiology Series 6 — Alveolar & Pleural Pressures, Compliance
- Zero = atmospheric: All pressures zeroed to 760 mmHg. Positive = above 760. Negative = below 760. Alveolar pressure at FRC = 0. Pleural pressure is ALWAYS negative (−3 to −8 mmHg).
- Why pleural pressure is always negative: Pleural space has no air molecules. No air = no inward force to oppose chest wall's outward spring → chest wall "wins" the tug-of-war → creates negative pressure. Pneumothorax = air enters pleural space → negative pressure lost → lung collapses.
- Inspiration mechanics: Diaphragm descends → thoracic volume ↑ → pleural pressure becomes MORE negative → lungs expand into pleural space → alveolar volume ↑ → alveolar pressure becomes NEGATIVE (below atm) → air flows IN down gradient. Maximum gradient = midway through inspiratory cycle.
- Expiration mechanics: Pleural pressure becomes LESS negative → lungs recoil → alveolar volume ↓ → alveolar pressure becomes POSITIVE (above atm) → air flows OUT. Until alveolar pressure re-equalizes to zero → exhalation stops.
- A-a gradient simple rule: Problem INTRINSIC to the lung (pneumonia, fibrosis, COPD) → A-a gradient INCREASED. Problem EXTRINSIC to the lung (opioid overdose, GBS, high altitude) → A-a gradient NORMAL. This is the most testable rule — no need to memorize a list.
- Tension vs open pneumothorax: Tension = hemodynamically significant → needle decompression (needle thoracostomy) first, then chest tube. Thoracostomy = tube into chest. Thoracotomy = surgical incision — different word, higher stakes.
Pressure Changes During Breathing
| Phase | Pleural Pressure | Alveolar Pressure | Air Flow Direction |
|---|---|---|---|
| At rest (FRC) | Negative (−3 to −5 cmH2O) | Zero (= atmospheric) | No flow |
| Inspiration | More negative (−8 to −10 cmH2O) | Becomes negative (−2 cmH2O) | Inward (atm to alveoli) |
| Expiration | Less negative (→ −3 cmH2O) | Becomes positive (+2 cmH2O) | Outward (alveoli to atm) |
A-a Gradient Master Rule
Lung problem → ↑ A-a gradient. Non-lung problem → normal A-a gradient.
Examples: Opioid OD suppresses respiratory drive → ↓ PAO2 → ↓ PaO2, but both fall equally → normal A-a gradient. COPD exacerbation → VQ mismatch → blood not oxygenating → ↑ gradient. High altitude → thin air → ↓ PAO2 globally → normal gradient (lungs fine). Pulmonary fibrosis → thickened diffusion barrier → ↑ gradient.
EP418
Pulmonary Pathophysiology Series 9 — O2 Content, Delivery & Hypoxemia Types
- O2 content equation: CaO2 = (1.34 × Hgb × SaO2) + (0.003 × PaO2). Hemoglobin-bound O2 is the dominant term — PaO2 dissolved fraction is minor. Anemia → ↓ Hgb → ↓ CaO2 (SaO2 normal). CO poisoning → ↓ SaO2 (CO occupies Hgb seats, 250× affinity vs O2) → ↓ CaO2 (PaO2 normal). Methemoglobinemia → Fe3+ can't carry O2 → ↓ SaO2 → ↓ CaO2.
- Oxygen flow pathway: Inspired O2 (PIO2 ~150 mmHg) → alveolar O2 (PAO2 ~100 mmHg, reduced by CO2 dilution) → diffuses to pulmonary capillary (PaO2 ~90–92 mmHg) → binds Hgb (SaO2). PAO2 is the source of PaO2 — if PAO2 drops, everything downstream drops.
- Hypoxia vs hypoxemia: Hypoxia = decreased O2 delivery to tissues (broader). Hypoxemia = low O2 in blood (one major cause of hypoxia). CO poisoning = hypoxia WITHOUT hypoxemia (PaO2 normal, SaO2 falsely normal on pulse ox).
- PIO2 vs FiO2: PIO2 = partial pressure of inspired O2 (~150 mmHg at sea level = 21% × 760). FiO2 = fractional concentration (21% normally). At high altitude: FiO2 still 21% but PIO2 lower (21% of smaller total pressure). On ventilator: FiO2 can be set to 100% — dramatically increases PIO2 and thus PAO2.
- PAO2 calculation: PAO2 = 150 − (PaCO2 / 0.8). R = respiratory quotient = 0.8 (CO2 produced / O2 consumed ratio — body is 80% efficient). CO2 "dilutes" oxygen in alveolus — why PAO2 (~100) is lower than PIO2 (~150).
Hypoxemia Comparison by Type
| Condition | Hgb | SaO2 | PaO2 | CaO2 | Key Feature |
|---|---|---|---|---|---|
| Normal | Normal | Normal | Normal | Normal | — |
| Anemia | ↓ | Normal | Normal | ↓ | Fewer buses, full seats |
| CO poisoning | Normal | ↓↓ | Normal | ↓↓ | Pulse ox reads falsely normal; cherry-red skin |
| Methemoglobinemia | Normal | ↓ | Normal | ↓ | Fe3+ can't carry O2; cyanosis, chocolate blood |
| COPD/emphysema | Normal (or ↑ EPO/polycythemia) | ↓ | ↓ | ↓ | ↑ PAO2 → all downstream ↓; body makes EPO → polycythemia |
| Polycythemia vera | ↑↑ | Normal | Normal | ↑↑ | More buses, all full — but ↑ viscosity |
Ventilator FiO2 Pearl
When reading a ventilator question, ALWAYS check the FiO2. It is NOT automatically 21%. Ventilators can deliver 100% O2 (FiO2 = 1.0). A patient with ARDS on FiO2 100% has a PAO2 = 713 − (PaCO2/0.8), not 100. Failing to check this will throw every calculation and clinical interpretation.
EP419
Pulmonary Pathophysiology Series 10 — A-a Gradient Deep Dive & Normal AA Gradient Causes
- A-a gradient = PAO2 − PaO2: Normal = 10–15 mmHg (increases with age: expected = [age + 10]/4). Reflects how well O2 moves from alveolus to capillary. Widened = something wrong at the lung level.
- Normal A-a gradient causes (lung is fine, input is low): Any cause of respiratory depression — opioid/barbiturate/benzo overdose, neuromuscular disease (ALS, MG, GBS, diaphragmatic paralysis). High altitude. Hypothyroidism (rarely). All reduce PIO2 or ventilation → ↓ PAO2 → ↓ PaO2, but EQUALLY → spread unchanged.
- Responsive to O2 supplementation: Normal A-a gradient hypoxemia responds well to supplemental O2 (you're just giving more input to a working system). High A-a gradient hypoxemia from shunt does NOT respond to O2.
- A-a gradient increases with age: Age-related mild fibrosis and inflammation → slightly thicker diffusion barrier → greater spread between PAO2 and PaO2. Formula [age+10]/4 gives expected value — useful to decide if a patient's gradient is truly elevated for their age.
- FiO2 effect on A-a gradient: If FiO2 is elevated (ventilator), PAO2 is much higher than usual. The A-a gradient calculation changes accordingly. Must use correct FiO2 in the alveolar gas equation or calculations are meaningless.
A-a Gradient: Normal vs Elevated — The Two-Rule System
The Two Rules You Need
Rule 1: Problem intrinsic to lung → A-a gradient elevated.
Rule 2: Problem extrinsic to lung → A-a gradient normal.
You will never need to memorize lists again.
| Cause of Hypoxemia | A-a Gradient | Responds to O2? |
|---|---|---|
| Opioid overdose (↓ RR) | Normal | Yes — lungs fine |
| GBS / MG (diaphragm weakness) | Normal | Yes |
| High altitude | Normal | Yes |
| Pulmonary fibrosis (diffusion block) | Elevated | Partially |
| VQ mismatch (COPD, pneumonia) | Elevated | Partially (blood still reaches alveoli) |
| True shunt (100%) | Elevated | NO — blood bypasses alveoli entirely |
EP421
Pulmonary Pathophysiology Series 11 — Shunts, VQ Mismatch, Transposition of Great Vessels
- Shunt definition: Blood bypasses well-ventilated alveoli entirely. Two types: (1) Intracardiac — blood flows RV→LV without going through pulmonary circulation. (2) Intrapulmonary — blood reaches collapsed or fluid-filled alveoli that contain no O2 (atelectasis, NRDS, pneumonia, lobar collapse).
- Shunts do NOT respond to supplemental O2: The blood that shunts never contacts any alveolus — extra O2 in normal alveoli helps the non-shunted fraction but cannot reach the shunting blood. If oxygenation does not improve with high FiO2, think shunt. NBME classic: newborn cyanosis, high O2 given → no improvement → cyanotic congenital heart defect.
- VSD vs shunt: Most VSDs are NOT shunts — blood flows L→R (oxygenated blood into RV) = acyanotic. Eisenmenger syndrome = VSD → pulmonary hypertension → flow reverses R→L → NOW it is a shunt. Tetralogy of Fallot = VSD + pulmonic stenosis → always R→L shunt → always cyanotic.
- Transposition of great vessels: RV drains into aorta (deoxygenated blood to body). LV drains into pulmonary artery (oxygenated blood recirculates to lungs). Two parallel circuits — incompatible with life unless mixing exists. Ductus arteriosus = mixing point. Alprostadil (PGE1) keeps ductus open until surgical correction.
- VQ mismatch: VQ ratio <1 = too much perfusion for available ventilation (consolidation, pneumonia, mucus plugging — blood reaches poorly ventilated alveoli). VQ ratio >1 or ∞ = too much ventilation for available perfusion (PE — blood can't get to ventilated alveoli = dead space). Normal VQ = 0.8.
- VQ mismatch vs shunt: Mismatch responds PARTIALLY to O2 (some good alveoli remain that can be maximized). Shunt does not respond at all. Think of shunt as extreme VQ mismatch (VQ = 0).
Transposition of Great Vessels — Mechanistic Walkthrough
Normal: RV → pulmonary artery → lungs → pulmonary veins → LA → LV → aorta → body.
TGV: RV → aorta (deoxygenated blood to body) | LV → pulmonary artery (oxygenated blood recirculates to lungs). Two closed loops — baby only survives if there is mixing (ASD, VSD, or patent ductus arteriosus).
TGV Timing on NBME
Baby appears normal for first hours to days because the ductus is still open (provides mixing, shunt <100%). As ductus closes (day 2–3), cyanosis worsens. O2 supplementation doesn't help. First step: Alprostadil (PGE1) to reopen/maintain ductus. Definitive: arterial switch operation.
VQ Mismatch — The Spectrum
| VQ Ratio | Meaning | Clinical Example | Dead Space? | Shunt? |
|---|---|---|---|---|
| 0 (zero) | No ventilation, perfusion OK | Complete shunt, atelectasis | No | Yes — 100% |
| <0.8 | Relative ↓ ventilation | Pneumonia, COPD, mucus plugging | No | Partial shunt physiology |
| 0.8 (normal) | Near-balanced V and Q | Healthy at rest | Minimal | No |
| >1 | Relative ↓ perfusion | PE, zone 1 lung | Yes | No |
| ∞ (infinity) | Ventilation only, no perfusion | Complete dead space (massive PE) | 100% | No |
EP422
Pulmonary Pathophysiology Series 12 — Lung Zones, V/Q at Apex vs Base, TB Location
- Both V and Q greater at base: Ventilation higher at base — alveoli at base are more deflated (higher intrapleural pressure at base), so more compliant and capture more O2 with each breath. Perfusion higher at base — greater hydrostatic pressure gradient between heart and lung base drives more flow.
- VQ ratio highest at apex: Both V and Q decrease from base to apex, but Q decreases FASTER than V. Therefore V/Q ratio is highest at apex (~3) and lowest at base (~0.6). Overall body average: ~0.8.
- TB loves the apex because: Apex has highest VQ ratio → relatively more O2 per blood flow → M. tuberculosis is an obligate aerobe that thrives in O2-rich microenvironment. "Analogously — you work 1 hour and earn $5 vs work 10 hrs for $10 — hourly rate is higher at apex."
- Lung zones (upright): Zone 1 (apex) = PA > Pa > Pv — alveolar pressure squishes capillaries = dead space. Zone 3 (base) = Pa > Pv > PA — capillaries always open = best perfusion. Zone 2 (middle) = Pa > PA > Pv — intermittent flow.
- Ventilator increases zone 1: Positive pressure ventilation ↑ alveolar pressure → squishes more apical capillaries → creates more zone 1 dead space. High PEEP: helpful for oxygenation but creates more dead space — balance needed. Barotrauma = alveolar rupture from excessive pressures.
- Supine/lateral position: When lying down, gravitational differences between apex and base are eliminated → VQ ratio becomes more uniform. The base-apex gradient nearly disappears. Also: during exercise, recruitment of apical alveoli reduces dead space.
Lung Zone Summary
| Zone | Location | Pressure Relationship | Blood Flow | VQ Ratio |
|---|---|---|---|---|
| Zone 1 | Apex | PA > Pa > Pv | Minimal (capillaries squished) | Highest (~3) = dead space |
| Zone 2 | Middle | Pa > PA > Pv | Intermittent (Starling resistor) | Intermediate (~1) |
| Zone 3 | Base | Pa > Pv > PA | Continuous (capillaries always open) | Lowest (~0.6) = best gas exchange |
Why the Apex Has Dead Space
Less blood flows to the apex → capillary hydrostatic pressure low → alveolar pressure (which is uniform throughout) exceeds capillary pressure → capillaries collapse. Ventilation continues (oxygen arrives) but no blood to collect it → wasted ventilation = dead space. Ventilators worsen this by further raising alveolar pressure.
EP425
Pulmonary Pathophysiology Series 13 — CO2 Transport, Bohr/Haldane, Obstructive vs Restrictive
- CO2 transport: 5% dissolved in plasma. 95% enters RBCs: carbonic anhydrase converts CO2 + H2O → H2CO3 → H+ + HCO3−. HCO3− exits RBC via chloride shift (bicarbonate-chloride antiporter). A small fraction binds Hgb as carbaminohemoglobin. HCO3− is the major CO2 transport form in blood and a critical plasma buffer.
- Chloride shift (high yield): As HCO3− leaves the RBC, Cl− enters to maintain electrical neutrality. This is why venous blood RBCs are slightly larger (more Cl− inside). High yield for step 1/2 integration questions.
- Bohr effect (O2 loading/unloading): High CO2 / acidic environment → Hgb converts from R (relaxed, holds O2) to T (tense, releases O2) form → O2 unloading at tissues. Opposite in lungs (low CO2, alkaline) → R form → O2 loading. NBME surrogate: acidosis = Bohr effect = rightward oxyhemoglobin curve shift.
- Haldane effect (CO2 loading/unloading): Oxygenated Hgb in lungs → releases CO2 (CO2 unloading). Deoxygenated Hgb in tissues → loads CO2 (CO2 loading). Higher O2 → less CO2 binding to Hgb.
- Obstructive pattern: Trouble getting air OUT (air trapping). FEV1 ↓↓, FVC ↓ → FEV1/FVC ratio <0.70. RV and FRC elevated (air trapping). Diseases: COPD, asthma, alpha-1-AT deficiency, bronchiectasis.
- Restrictive pattern: Trouble getting air IN (stiff lungs). FEV1 ↓, FVC ↓↓ (FVC drops MORE because you can't fill lungs to begin with) → FEV1/FVC ratio normal or elevated (>0.70). All lung volumes ↓. Diseases: ILD, sarcoidosis, fibrosis, pneumoconioses, NRDS. Emphysema: DLCO ↓↓ (destroyed alveoli). Chronic bronchitis: DLCO normal (alveoli intact, airway problem only).
Obstructive vs Restrictive — Complete Comparison
| Feature | Obstructive | Restrictive |
|---|---|---|
| Core problem | Can't get air OUT (air trapping) | Can't get air IN (stiff/small lungs) |
| FEV1 | ↓↓ | ↓ |
| FVC | ↓ (less than FEV1 drop) | ↓↓ (more than FEV1 drop) |
| FEV1/FVC ratio | ↓ (<0.70) — DEFINING | Normal or ↑ (>0.70) |
| TLC | ↑ (air trapping) | ↓ (can't fill) |
| RV | ↑↑ | ↓ |
| DLCO | Emphysema ↓↓; Chronic bronchitis normal | ↓ (thickened barrier) |
| Examples | COPD, asthma, alpha-1-AT, bronchiectasis | IPF, sarcoidosis, pneumoconioses, NRDS, obesity |
DLCO Distinguishes Emphysema from Chronic Bronchitis
Emphysema: Alveoli destroyed → ↓ surface area for diffusion → ↓ DLCO. A-a gradient ↑.
Chronic bronchitis: Airways plugged with mucus, but alveoli mostly intact → DLCO normal. Reid index ↑ (mucus gland hypertrophy ratio). A-a gradient roughly normal.
NBME pearl: "Obstructive pattern + ↓ DLCO" = emphysema. "Obstructive pattern + normal DLCO" = chronic bronchitis.
Carbonic Anhydrase Integrations (High Yield)
- CO2 + H2O → H2CO3 → H+ + HCO3− (by carbonic anhydrase in RBCs)
- Same enzyme needed for CSF production → acetazolamide (CA inhibitor) used for pseudotumor cerebri and open-angle glaucoma
- Acetazolamide → ↓ HCO3− reabsorption in PCT → Type 2 RTA + metabolic acidosis + hypokalemia (unique among diuretics)
- Chloride shift: HCO3− leaves RBC → Cl− enters → maintains electrical neutrality in venous blood
Obstructive Lung Disease
Asthma, COPD, alpha-1-antitrypsin deficiency, and cystic fibrosis pharmacology are covered across three dedicated episodes. The treatment ladder (SABA → ICS → LABA/leukotriene antagonist → oral steroids) is explicit and testable, and the smoking podcast ties COPD risk to a broad constellation of systemic diseases that appear throughout NBME questions.
EP397
Pulmonary Pathophysiology Series 3 — Asthma Pharmacology, Treatment Ladder, Steroid Side Effects
- Short-acting bronchodilators (acute exacerbation): SABA = albuterol (beta-2 agonist, short-acting). SAMA = ipratropium (muscarinic antagonist, short-acting). Both used for acute asthma AND acute COPD exacerbation. Memory: alphabetically earlier = shorter-acting (albuterol A, ipratropium I = earlier than salmeterol S, tiotropium T).
- Albuterol side effects: Mild beta-1 spillover → tachycardia. Also activates Na/K-ATPase → drives K+ into cells → useful for acute hyperkalemia treatment (along with calcium gluconate, insulin/glucose).
- Long-acting bronchodilators (maintenance ONLY — never for acute exacerbations): LABAs = salmeterol, formoterol. LAMA = tiotropium. LABAs as monotherapy in asthma → increased fatal asthma attacks (Black Box Warning). ALWAYS combine with ICS.
- Asthma treatment ladder: Step 1 = SABA PRN. Step 2 = add ICS (budesonide, fluticasone). Step 3 = add LABA OR leukotriene antagonist (montelukast, zafirlukast). Step 4 = oral corticosteroids. COPD ladder differs: Step 2 = LABA/LAMA (not ICS). ICS is Step 3 in COPD.
- IV corticosteroids in hospital: Mandatory for acute asthma AND acute COPD exacerbation. Oral steroids on discharge (3–5 days) to prevent late-phase rebound. Mechanism: bind DNA response elements → inhibit NF-κB → ↓ transcription of leukotriene/histamine/TNF genes. Also inhibit phospholipase A2 → ↓ arachidonic acid → ↓ leukotrienes and prostaglandins.
- Steroid side effects (chronic use): Oropharyngeal candidiasis (inhaled — rinse mouth after use, treat with nystatin swish-and-swallow or oral azole). Cushingoid features (buffalo hump, moon face). HPA suppression → stress dose steroids needed for surgery or acute illness. Osteoporosis → bisphosphonates. Peptic ulcer disease → PPI. Immunosuppression → PCP pneumonia (TMP-SMX prophylaxis).
Bronchodilator Reference Table
| Drug | Class | Duration | Use | Key Pearl |
|---|---|---|---|---|
| Albuterol | Beta-2 agonist | Short-acting | Acute exacerbation (asthma + COPD) | Also treats hyperkalemia; tachycardia side effect |
| Ipratropium | Muscarinic antagonist | Short-acting | Acute exacerbation (asthma + COPD) | Combo with albuterol in severe exacerbations |
| Salmeterol / Formoterol | Beta-2 agonist | Long-acting (LABA) | Maintenance only (never acute) | Black box: fatal asthma if monotherapy; always with ICS |
| Tiotropium | Muscarinic antagonist | Long-acting (LAMA) | Maintenance (COPD preferred Step 2) | Reduced COPD exacerbations |
| Budesonide / Fluticasone | ICS | Daily | Asthma Step 2; COPD Step 3 | Oral candidiasis; rinse mouth; Cushing features if high dose |
| Omalizumab | Anti-IgE monoclonal Ab | Biologic | Severe allergic asthma with high IgE | Binds constant region of IgE → prevents mast cell binding |
COPD vs Asthma Ladder Difference
Critical NBME distinction: In COPD, Step 2 is LABA or LAMA (long-acting bronchodilator), NOT ICS. Inhaled corticosteroids are Step 3 in COPD. In asthma, ICS is Step 2 (immediately after PRN SABA). Putting ICS as Step 2 for COPD is wrong on the exam.
Steroid Side Effects — Exam-Ready Summary
- Short-term: hyperglycemia, leukocytosis (demargination), mood changes
- Long-term: Cushing features (buffalo hump, moon face, purple striae), osteoporosis → bisphosphonate prophylaxis, PUD → PPI, immunosuppression → PCP prophylaxis with TMP-SMX
- Inhaled: oropharyngeal/esophageal candidiasis → treat with nystatin or oral fluconazole, advise mouth rinse
- Withdrawal: HPA axis suppression → adrenal insufficiency crisis (persistent hypotension unresponsive to pressors = stress dose hydrocortisone)
EP402
Pulmonary Pathophysiology Series 4 — Aspirin-Induced Asthma, EGPA, Omalizumab, Pulmonary HTN Intro, CF Drugs
- Aspirin-exacerbated respiratory disease (AERD): NSAIDs/aspirin block COX → arachidonic acid shunted to lipoxygenase pathway → ↑↑ leukotrienes (LTC4, LTD4, LTE4 act on CYSLT1 receptor → bronchoconstriction). LTB4 = potent neutrophil chemotactic factor. Associated with nasal polyps (also in CF, GPA/Wegener's, chronic rhinosinusitis). Treat with leukotriene antagonists: montelukast/zafirlukast (CYSLT1 blockers) or zileuton (5-LOX inhibitor).
- EGPA (Churg-Strauss, eosinophilic granulomatosis with polyangiitis): Unmasking phenomenon — patient has intractable asthma on steroids; steroids withdrawn, replaced with montelukast → asthma worsens dramatically + peripheral neuropathy + renal dysfunction + cardiac issues + p-ANCA (anti-MPO). Treat with steroids + cyclophosphamide. Classic steroid-unmasking NBME integration.
- Omalizumab: Monoclonal antibody against Fc region (constant region) of IgE → prevents IgE from binding Fc-epsilon receptors on mast cells → prevents cross-linking and degranulation. Used for severe allergic asthma with elevated IgE levels.
- Idiopathic pulmonary arterial hypertension (iPAH): Young female + BMPR2 mutation. Mechanism: ↑ endothelin (powerful vasoconstrictor) + ↓ nitric oxide + ↓ prostaglandins. Treatment: endothelin receptor antagonists (bosentan, ambrisentan), PDE-5 inhibitors (sildenafil → ↑ cGMP → smooth muscle relaxation), prostaglandin analogs (iloprost, epoprostenol). NEVER combine sildenafil with nitrates (severe hypotension).
- Cystic fibrosis airway clearance: Thick mucus from ↓ CFTR function (Chr 7, ΔF508 most common). N-acetylcysteine breaks disulfide bonds in mucus. Dornase alfa (anti-DNase / DNase) breaks phosphodiester bonds in DNA from dead inflammatory cells. Both thin secretions. Pseudomonas = classic CF pathogen colonizing mucus-obstructed airways.
- Nasal polyps differential: CF, aspirin-exacerbated respiratory disease, GPA (Wegener's), chronic rhinosinusitis with nasal polyposis. On NBME, "mucosal overgrowth in nose" = nasal polyps.
Arachidonic Acid Pathway — The Branching Point
| Pathway | Enzyme | Products | Inhibited By |
|---|---|---|---|
| COX pathway | Cyclooxygenase (COX-1/2) | Prostaglandins, thromboxane | Aspirin, NSAIDs |
| LOX pathway | 5-Lipoxygenase | Leukotrienes (LTB4, LTC4, LTD4, LTE4) | Zileuton (5-LOX inhibitor) |
| Leukotriene receptor | CYSLT1 receptor | Bronchoconstriction, mucus, vascular permeability | Montelukast, zafirlukast |
EGPA Unmasking Pattern
Patient has severe asthma controlled by steroids → steroids replaced by montelukast as "steroid-sparing" agent → asthma worsens dramatically + NEW symptoms (peripheral neuropathy, renal involvement, eosinophilia, p-ANCA positive). The steroids were suppressing EGPA, not just asthma. Montelukast cannot suppress EGPA. Treatment = return to steroids + cyclophosphamide.
iPAH Treatment Mechanism Summary
- Endothelin receptor antagonists (bosentan, ambrisentan): Block ET-1 → vasodilation + ↓ smooth muscle proliferation
- PDE-5 inhibitors (sildenafil, tadalafil): ↓ cGMP breakdown → ↑ cGMP → smooth muscle relaxation → vasodilation (same as NO effect)
- Prostacyclin analogs (iloprost, epoprostenol, treprostinil): Vasodilation + platelet inhibition
- Avoid with sildenafil: Nitrates, alpha-1 blockers, tricyclics, dihydropyridine CCBs → severe hypotension
EP383
The Clutch Smoking Podcast — Systemic Disease Integrations, Screening, Cessation
- Smoking as #1 risk factor for: Lung cancer, COPD, bladder cancer, renal cell carcinoma, pancreatic cancer, peripheral arterial disease, MI, AAA (abdominal aortic aneurysm), multifocal atrial tachycardia (3+ P-wave morphologies). On average subtracts ~14 years from lifespan.
- Lung cancer screening: Age 50–80 + ≥20 pack-year history + currently smokes OR quit within past 15 years → annual low-dose CT scan. Quit >15 years ago = no screening needed. Stop screening if terminal illness (e.g., pancreatic cancer) makes treatment meaningless.
- 15-year rule: If you quit smoking for ≥15 years, lung cancer risk returns to near non-smoker levels. This number appears in screening guidelines and risk-reduction questions.
- OB integrations: Smoking during pregnancy → nicotine vasoconstricts placental arteries → asymmetric IUGR (size < dates in 2nd/3rd trimester). In household → ↑ SIDS risk. Placental abruption (painful 3rd-trimester bleeding) linked to smoking. Women >35 who smoke = contraindication to estrogen-containing contraceptives (DVT/PE/MI risk). Tamoxifen/raloxifene + smoking = ↑ VTE risk.
- Buerger's disease (thromboangiitis obliterans): Ischemic digits/toes in heavy smoker. Treat with dihydropyridine CCB for symptoms. Cure = stop smoking. Complete cessation resolves disease.
- Cessation pharmacotherapy: Nicotine replacement (patches, gum). Bupropion (NRI/NDRI) — avoid in seizure disorders, anorexia/bulimia (lowers seizure threshold). Varenicline — partial nicotinic ACh receptor agonist (blocks nicotine reward). Cotinine (urine) = biomarker for tobacco exposure (employment testing).
Smoking-Related Disease Quick Reference
| Disease | Smoking Connection | NBME Pearl |
|---|---|---|
| Lung cancer | #1 risk factor; 20 pack-year → screen w/ low-dose CT | All 4 major types, but squamous cell = cavitating central |
| COPD/Emphysema | Smoke → ↑ protease activity → alveolar destruction | Quitting slows decline; only intervention improving survival |
| Bladder cancer | #1 modifiable risk factor | Painless hematuria in smoker → cystoscopy |
| Pancreatic cancer | #1 risk factor | Painless jaundice + weight loss + Courvoisier sign |
| Buerger's disease | Essentially only occurs in smokers | Ischemic digits, young male, heavy smoker; cure = stop smoking |
| Spontaneous pneumothorax | Smoking → apical blebs → rupture | Young thin male + sudden pleuritic chest pain + ↓ breath sounds |
| Multifocal atrial tachycardia | #1 risk factor | 3+ P-wave morphologies on EKG; treat underlying COPD; no beta-blockers |
Smoking Is NOT a Risk Factor for Mesothelioma
High yield negative: mesothelioma risk factor is asbestos exposure, not smoking. Asbestos + smoking = synergistic for lung cancer (but mesothelioma itself is not smoking-related). On NBME: "shipyard worker, decades of asbestos exposure, hemorrhagic pleural effusion" = mesothelioma. Psamomma bodies (laminated calcifications) on biopsy.
Infections & Pneumonia
Pulmonary infections appear across many episodes as integrations — GBS presenting as respiratory failure needing intubation, sickle cell autosplenectomy leading to pneumococcal pneumonia, immunosuppressed patients on chronic steroids developing PCP. The RR-66 episode integrates GBS respiratory failure with pneumonia in a high-yield rapid-review format.
RR 66EP351
Rapid Review 66 — GBS Respiratory Failure, Sickle Cell Pneumococcal Pneumonia, Rheumatic Fever
- GBS respiratory failure: Any mucosal infection (GI, respiratory, GU) → ascending symmetric paralysis → diaphragm paralysis → respiratory failure requiring intubation. CSF: albuminocytologic dissociation (↑↑ protein, 0–3 WBCs). Next step = endotracheal intubation. Treat: IVIG (or plasmapheresis).
- Sickle cell + pneumococcal pneumonia: African-American child with high fevers, lobar infiltrate, gram-positive diplococci, leukocytosis → mechanism = autosplenectomy (repeated splenic infarctions → no spleen). Encapsulated organisms: Strep pneumo, H. influenzae, N. meningitidis. Treat with 3rd-gen cephalosporin (ceftriaxone/cefotaxime).
- Steroid-induced PCP: Chronic steroid use → immunosuppression → Pneumocystis jirovecii pneumonia (interstitial infiltrates, silver-stain organisms on sputum). Prophylaxis with TMP-SMX. "Legionella" also presents with silver-stain positive organisms + heavy smoking history + water exposure.
- Rheumatic fever + mitral stenosis: Group A Strep pharyngitis → molecular mimicry → antibodies attack myocardium. Aschoff bodies on biopsy. Biggest risk factor for mitral stenosis = rheumatic fever. Treatment: penicillin + NSAIDs. Secondary prophylaxis prevents recurrence.
- Aspiration pneumonia location: Right lower lobe in upright patients. Right upper lobe posterior segment in bedridden/supine patients. Anaerobic organisms common (foul-smelling sputum). Treat with clindamycin or amoxicillin-clavulanate.
Pulmonary Infections Requiring Intubation
| Condition | Mechanism | CSF | Treatment |
|---|---|---|---|
| Guillain-Barré Syndrome | Demyelination → ascending paralysis → diaphragm | ↑↑ protein, <5 WBC (albuminocytologic dissociation) | Intubate first; then IVIG or plasmapheresis |
| Myasthenia gravis crisis | Anti-AChR antibodies → NMJ failure → respiratory muscle weakness | Normal | Intubate; pyridostigmine (not in crisis); plasmapheresis/IVIG |
| ALS (late stage) | UMN + LMN → diaphragm weakness | Normal | Non-invasive ventilation (BiPAP); riluzole |
Pneumonia Empiric Coverage by Setting
CAP (outpatient, mild): Azithromycin or doxycycline. CAP (inpatient): Beta-lactam + macrolide OR respiratory fluoroquinolone. HAP/VAP: Anti-pseudomonal (pip-tazo, cefepime) ± vancomycin (MRSA). Aspiration: Clindamycin or amoxicillin-clavulanate (anaerobic coverage). Immunocompromised/PCP: TMP-SMX (high dose treatment, lower dose prophylaxis).
Interstitial & Restrictive Disease
Sarcoidosis exemplifies the multi-system granulomatous disease pattern — it is simultaneously a restrictive lung disease, a cause of hypercalcemia (via macrophage 1-alpha-hydroxylase), a cause of bilateral Bell's palsy (neurosarcoidosis), a cardiac infiltrator causing restrictive cardiomyopathy and heart block, and a dermatological diagnosis (erythema nodosum = good prognosis, lupus pernio = poor prognosis). Mastering sarcoidosis means mastering multi-system integration.
EP411
The Clutch Sarcoidosis Podcast — Multi-System Granulomatous Disease
- Sarcoidosis basics: Non-caseating granulomas. Giant cells + epithelioid macrophages. Most common organ = lungs (~90%). Second most common = skin. Demography: African-Americans (most common in US) AND Scandinavians — do not pigeonhole to one group. Women > men. Most common outcome = resolution without recurrence (>95%).
- Lofgren syndrome (good prognosis triad): Bilateral hilar lymphadenopathy + arthritis (knees, ankles) + erythema nodosum. Erythema nodosum = lower extremity tender red lesions = predictor of excellent prognosis. Lupus pernio (raised purple facial lesions in malar distribution) = predictor of poor prognosis.
- Hypercalcemia mechanism: Epithelioid macrophages in granulomas express 1-alpha-hydroxylase → ↑ 1,25-(OH)2 vitamin D (calcitriol) → ↑ GI calcium absorption → hypercalcemia. PTH is normal or low (negative feedback). NBME can give "high calcitriol + normal PTH + hypercalcemia" — that's sarcoidosis (not PTH-dependent).
- Lab findings: ↑ ACE (angiotensin-converting enzyme) — from granuloma endothelial cells. ↑ calcitriol. Hypercalcemia. Elevated LFTs if liver granulomas (usually asymptomatic). Unreliable PPD/TB skin test (anergy from T-cell dysregulation).
- Treatment: Asymptomatic = observe (most resolve). Symptomatic = steroids (first-line). Steroid failure → methotrexate (↓DHFR, hepatotoxic, pulmonotoxic), azathioprine. Dermatologic manifestations = hydroxychloroquine (annual ophthalmology exam for retinal toxicity). Ursodiol for symptomatic liver sarcoidosis.
- Extra-pulmonary: Heart — restrictive cardiomyopathy + conduction blocks (heart block) + ventricular aneurysm. Eyes — uveitis (most common eye finding). CNS — bilateral Bell's palsy (CN7) most classic; sensory neuropathy; central DI (granulomas in hypothalamus destroy ADH neurons). Liver — granulomas (↑ LFTs, usually asymptomatic).
Sarcoidosis Multi-System Reference
| System | Manifestation | Key Pearl |
|---|---|---|
| Lungs (90%) | Interstitial lung disease, restrictive pattern, bilateral hilar lymphadenopathy | Fine crackles; FEV1/FVC normal or ↑; ↓ DLCO |
| Skin (2nd most common) | Erythema nodosum (good prognosis), lupus pernio (poor prognosis), granuloma annulare (hands/feet) | Skin sarcoid = hydroxychloroquine |
| Calcium | Hypercalcemia via ↑ calcitriol from macrophage 1-alpha-OH | PTH normal or low (autonomous production, not feedback-driven) |
| Heart | Restrictive cardiomyopathy, heart block, arrhythmias | Infiltration → sarcomas pattern → no diastolic filling |
| Eye | Uveitis (most common) | Painful red eye + photophobia; treat with topical steroids |
| Neuro | Bilateral Bell's palsy (CN7), sensory neuropathy, central DI | Bilateral facial weakness → think neurosarcoidosis first |
| Liver | Granulomas (usually asymptomatic) | Symptomatic = ursodiol; most common cause ↑ ALP in sarcoidosis |
Sarcoidosis Prognosis Pearls
Good prognosis: Erythema nodosum, Lofgren syndrome, acute presentation, hilar adenopathy only.
Poor prognosis: Lupus pernio, African-American patients, chronic uveitis, cardiac involvement, neurological involvement, stage 4 (fibrosis).
Most likely outcome overall: Spontaneous resolution without recurrence — this is the NBME answer for "most likely outcome."
PPD Anergy in Sarcoidosis
Sarcoidosis causes anergy — unreliable TB skin test (PPD). This is because sarcoidosis involves T-cell dysregulation: peripheral blood T-cells are functionally depleted (they concentrate in granulomas at affected sites). A negative PPD in a patient with bilateral hilar lymphadenopathy does NOT rule out TB — use interferon-gamma release assay (IGRA) or biopsy instead.